• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿司匹林通过 miR-491/ABCG2 增强肝癌侧群细胞对阿霉素的敏感性。

Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2.

机构信息

Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China

Department of Gastroenterology, The First Affiliated Hospital, Gannan Medical University, Ganzhou 341000, China.

出版信息

Biosci Rep. 2018 Nov 9;38(6). doi: 10.1042/BSR20180854. Print 2018 Dec 21.

DOI:10.1042/BSR20180854
PMID:30120100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6239265/
Abstract

To explore whether aspirin (ASA) enhances the sensitivity of hepatocellular carcinoma (HCC) side population (SP) cells to doxorubicin (Doxo) via miR-491/ATP-binding cassette sub-family G member 2 (ABCG2). Non-SP and SP cells were isolated from MHCC-97L cell line using flow cytometry analysis and fluorescence-activated cell sorting. Colony formation assay was performed to determine the colony-formation ability of cells. Cell viability of SP cells was determined with the MTT assay. Luciferase reporter assay was applied in confirming the binding between miR-491 and ABCG2. Although the Doxo treatment lowered the colony-formation ability of both non-SP and SP cells, the colony-formation ability of SP cells was 2-fold higher than that of non-SP cells (<0.05). Doxo slightly inhibited the cell viability of SP cells in a concentration-dependent manner; the addition of ASA dramatically enhanced the inhibitory effect of Doxo on SP cell viability in a concentration-dependent manner (<0.05). Compared with non-SP cells, the miR-491 expression was significantly decreased in SP cells, which was significantly reversed by ASA (<0.05). miR-491 directly controlled the ABCG2 expression. In the presence of Doxo, miR-491 inhibitor reduced the inhibitory effect of ASA on the cell viability of SP cells, which was significantly reversed by knockdown of ABCG2 (<0.05). ASA enhanced the sensitivity of SP cells to Doxo via regulating the miR-491/ABCG2 signaling pathway.

摘要

探讨阿司匹林(ASA)是否通过 miR-491/ATP 结合盒亚家族 G 成员 2(ABCG2)增强肝癌(HCC)侧群(SP)细胞对阿霉素(Doxo)的敏感性。使用流式细胞术分析和荧光激活细胞分选从 MHCC-97L 细胞系中分离非 SP 和 SP 细胞。集落形成实验用于确定细胞的集落形成能力。MTT 测定法用于测定 SP 细胞的细胞活力。荧光素酶报告测定法用于确认 miR-491 与 ABCG2 之间的结合。虽然 Doxo 处理降低了非 SP 和 SP 细胞的集落形成能力,但 SP 细胞的集落形成能力是非 SP 细胞的 2 倍(<0.05)。Doxo 以浓度依赖性方式轻微抑制 SP 细胞的细胞活力;ASA 的加入以浓度依赖性方式显着增强 Doxo 对 SP 细胞活力的抑制作用(<0.05)。与非 SP 细胞相比,SP 细胞中的 miR-491 表达明显降低,ASA 明显逆转(<0.05)。miR-491 直接控制 ABCG2 的表达。在 Doxo 存在的情况下,miR-491 抑制剂降低了 ASA 对 SP 细胞活力的抑制作用,ABCG2 的敲低明显逆转(<0.05)。ASA 通过调节 miR-491/ABCG2 信号通路增强了 SP 细胞对 Doxo 的敏感性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/b2d25aabe30d/bsr-38-bsr20180854-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/fd6530e13fb8/bsr-38-bsr20180854-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/e438931186a7/bsr-38-bsr20180854-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/151288c106cf/bsr-38-bsr20180854-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/496022e42607/bsr-38-bsr20180854-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/b2d25aabe30d/bsr-38-bsr20180854-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/fd6530e13fb8/bsr-38-bsr20180854-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/e438931186a7/bsr-38-bsr20180854-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/151288c106cf/bsr-38-bsr20180854-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/496022e42607/bsr-38-bsr20180854-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c796/6239265/b2d25aabe30d/bsr-38-bsr20180854-g5.jpg

相似文献

1
Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2.阿司匹林通过 miR-491/ABCG2 增强肝癌侧群细胞对阿霉素的敏感性。
Biosci Rep. 2018 Nov 9;38(6). doi: 10.1042/BSR20180854. Print 2018 Dec 21.
2
Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.ABCG2表达及侧群分析确定肝癌细胞系MHCC-97L中的内在药物外排及其受Akt信号传导的调节。
Carcinogenesis. 2008 Dec;29(12):2289-97. doi: 10.1093/carcin/bgn223. Epub 2008 Sep 26.
3
miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.miR-122 通过靶向 Wnt/β-catenin 通路抑制 MDR1 增强肝癌细胞对奥沙利铂的敏感性。
Exp Mol Pathol. 2019 Feb;106:34-43. doi: 10.1016/j.yexmp.2018.10.009. Epub 2018 Oct 26.
4
An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.一种异紫堇定衍生物(d-ICD)通过下调肝细胞癌中IGF2BP3的表达来抑制耐药性。
Oncotarget. 2015 Sep 22;6(28):25149-60. doi: 10.18632/oncotarget.4438.
5
The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells.抑制 ABCB1/MDR1 或 ABCG2/BCRP 可使多柔比星消除肝癌干细胞。
Sci Rep. 2021 May 24;11(1):10791. doi: 10.1038/s41598-021-89931-9.
6
SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.SOX9 通过上调 ABCG2 表达增强肝癌对索拉非尼的耐药性。
Biomed Pharmacother. 2020 Sep;129:110315. doi: 10.1016/j.biopha.2020.110315. Epub 2020 Jun 15.
7
Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.舌鳞状细胞癌中miR-222-ABCG2调控模块的失调导致化疗耐药并增强迁移/侵袭潜能。
Oncotarget. 2015 Dec 29;6(42):44538-50. doi: 10.18632/oncotarget.6253.
8
Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p.双氢睾酮诱导三阴性乳腺癌MDA-MB-231细胞对阿霉素产生化疗耐药性,且不依赖ABCG2和miR-328-3p 。
Curr Mol Pharmacol. 2021;14(5):860-870. doi: 10.2174/1874467214666210531170355.
9
miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.miR-505 通过直接靶向 HMGB1 抑制 Akt 通路增强肝癌细胞对阿霉素的细胞毒性。
Biomed Pharmacother. 2018 Aug;104:613-621. doi: 10.1016/j.biopha.2018.05.087. Epub 2018 May 25.
10
miR-33a expression sensitizes Lgr5+ HCC-CSCs to doxorubicin via ABCA1.miR-33a 通过 ABCA1 使 Lgr5+ HCC-CSCs 对阿霉素敏感。
Neoplasma. 2017;64(1):81-91. doi: 10.4149/neo_2017_110.

引用本文的文献

1
Role of CD133 antibody-conjugated nanocarrier in enhancing the targetability of hepatocellular carcinoma stem cells.CD133抗体偶联纳米载体在增强肝癌干细胞靶向性中的作用
Sci Rep. 2025 Aug 19;15(1):30441. doi: 10.1038/s41598-025-14435-9.
2
Platelets in Hepatocellular Carcinoma-From Pathogenesis to Targeted Therapy.肝细胞癌中的血小板——从发病机制到靶向治疗
Cancers (Basel). 2025 Jul 18;17(14):2391. doi: 10.3390/cancers17142391.
3
Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Advances.阿司匹林在癌症治疗中的应用:药理学与纳米技术进展

本文引用的文献

1
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment.癌症干细胞在耐药性中的作用及其在癌症治疗中的治疗意义
Stem Cells Int. 2018 Feb 28;2018:5416923. doi: 10.1155/2018/5416923. eCollection 2018.
2
Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults.阿司匹林的使用与韩国成年人全国队列研究中肝细胞癌的风险。
Sci Rep. 2018 Mar 21;8(1):4968. doi: 10.1038/s41598-018-23343-0.
3
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
Int J Nanomedicine. 2025 Feb 23;20:2327-2365. doi: 10.2147/IJN.S505636. eCollection 2025.
4
MiRNAs: main players of cancer drug resistance target ABC transporters.微小RNA:癌症耐药性的主要作用靶点是ABC转运蛋白。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 14. doi: 10.1007/s00210-024-03719-y.
5
MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.微小RNA在癌细胞对多柔比星耐药性发展中的作用:靶向ATP结合盒转运蛋白
Front Pharmacol. 2024 Nov 29;15:1486783. doi: 10.3389/fphar.2024.1486783. eCollection 2024.
6
miRTarBase 2025: updates to the collection of experimentally validated microRNA-target interactions.miRTarBase 2025:经实验验证的微小RNA-靶标相互作用集合的更新
Nucleic Acids Res. 2025 Jan 6;53(D1):D147-D156. doi: 10.1093/nar/gkae1072.
7
Synergistic antitumor efficacy of aspirin plus lenvatinib in hepatocellular carcinoma via regulating of diverse signaling pathways.阿司匹林联合乐伐替尼通过调节多种信号通路对肝细胞癌产生协同抗肿瘤疗效。
Cell Death Discov. 2023 Nov 16;9(1):416. doi: 10.1038/s41420-023-01664-y.
8
ncRNADrug: a database for validated and predicted ncRNAs associated with drug resistance and targeted by drugs.ncRNA 药物:一个验证和预测与药物耐药性相关的 ncRNA 数据库,以及这些 ncRNA 被药物靶向的数据库。
Nucleic Acids Res. 2024 Jan 5;52(D1):D1393-D1399. doi: 10.1093/nar/gkad1042.
9
Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.改善门静脉高压的管理:非病因治疗在肝硬化中的潜在益处。
J Clin Med. 2023 Jan 25;12(3):934. doi: 10.3390/jcm12030934.
10
Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers.化疗耐药相关ABC蛋白在肝胆胰及胃肠道癌症中的表达
Cancers (Basel). 2022 Jul 20;14(14):3524. doi: 10.3390/cancers14143524.
晚期不可切除肝细胞癌患者的系统治疗:治疗方法的出现
J Gastrointest Cancer. 2018 Jun;49(2):107-115. doi: 10.1007/s12029-018-0065-8.
4
Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC.肝癌干细胞的表面标志物及肝癌的创新靶向治疗策略
Oncol Lett. 2018 Feb;15(2):2039-2048. doi: 10.3892/ol.2017.7568. Epub 2017 Dec 8.
5
Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis.通过调节活性氧和糖酵解,金诺芬消除了具有干细胞样特征的肿瘤细胞亚群。
Cell Death Dis. 2018 Jan 24;9(2):89. doi: 10.1038/s41419-017-0159-4.
6
The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity.miRNAs 在肝脏疾病和毒性的病理生理学中的作用。
Int J Mol Sci. 2018 Jan 16;19(1):261. doi: 10.3390/ijms19010261.
7
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.晚期肝细胞癌的全身化疗:过去、现在与未来
Diseases. 2015 Dec 1;3(4):360-381. doi: 10.3390/diseases3040360.
8
Characteristics of primary side population cervical cancer cells.原发性侧群宫颈癌细胞的特征。
Oncol Lett. 2017 Sep;14(3):3536-3544. doi: 10.3892/ol.2017.6606. Epub 2017 Jul 18.
9
Chemotherapy for hepatocellular carcinoma: The present and the future.肝细胞癌的化疗:现状与未来
World J Hepatol. 2017 Jul 28;9(21):907-920. doi: 10.4254/wjh.v9.i21.907.
10
The Recent Advances on Liver Cancer Stem Cells: Biomarkers, Separation, and Therapy.肝癌干细胞的最新进展:标志物、分离和治疗。
Anal Cell Pathol (Amst). 2017;2017:5108653. doi: 10.1155/2017/5108653. Epub 2017 Jul 27.